公开(公告)号：US20150299182A1

公开(公告)日：2015-10-22

申请号：US14441133

申请日：2013-11-08

Applicant: Array BioPharma Inc. ,  Amgen Inc.

Inventor： Sylvie Asselin ,  Lisa Brett ,  Ying Chen ,  Donald T. Corson ,  Andrew Cosbie ,  Robert Farrell ,  Indrani W. Gunawardana ,  Jinkun Huang ,  Jonathan W. Lane ,  Dennis Lei ,  Christopher M. Lindemann ,  Van Luu ,  Coralee G. Mannila ,  Robert Milburn ,  Henry Morrison ,  Helming Tan ,  Jason Tedrow ,  Daniel J. Watson

IPC: C07D417/14

CPC classification number: C07D417/14 ,  C07B2200/13

Abstract: The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.

Abstract translation: 本发明涉及（1S）-1- [5 - （{3 - [（2-甲基吡啶-3-基）氧基] -5-（吡啶-2-基硫烷基）吡啶-2-基} 氨基）-1,2,4-噻二唑-3-基]乙烷-1,2-二醇，包括这种结晶多晶型物的药物组合物及其制备方法。 本发明还涉及治疗糖尿病相关病症的方法，包括将这种固态形式或其组合物施用于受试者，以及在制备药物中使用这种结晶多晶型物。

公开(公告)号：US20200308143A1

公开(公告)日：2020-10-01

申请号：US16607940

申请日：2018-06-29

Applicant: AMGEN INC.

Inventor： Sebastien Caille ,  Kyle Quasdorf ,  Philipp Roosen ,  Xianqing Shi ,  Andrew Cosbie ,  Fang Wang ,  Zufan Wu ,  Archana Neergunda ,  Bin Peter Quan ,  Lianxiu Guan

IPC: C07D401/12 ,  C07D241/04

Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (I)

公开(公告)号：US12269811B2

公开(公告)日：2025-04-08

申请号：US18359467

申请日：2023-07-26

Applicant: Amgen Inc.

Inventor： Sebastien Caille ,  Kyle Quasdorf ,  Philipp C. Roosen ,  Xianqing Shi ,  Andrew Cosbie ,  Fang Wang ,  Zufan Wu ,  Archana Neergunda ,  Bin Peter Quan ,  Lianxiu Guan

IPC: C07D295/205 ,  C07D213/75 ,  C07D241/04 ,  C07D401/12

Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (1)

公开(公告)号：US11753394B2

公开(公告)日：2023-09-12

申请号：US17324867

申请日：2021-05-19

Applicant: AMGEN INC.

Inventor： Sebastien Caille ,  Kyle Quasdorf ,  Philipp C. Roosen ,  Xianqing Shi ,  Andrew Cosbie ,  Fang Wang ,  Zufan Wu ,  Archana Neergunda ,  Bin Peter Quan ,  Lianxiu Guan

IPC: C07D401/12 ,  C07D241/04

CPC classification number: C07D401/12 ,  C07D241/04

Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.

公开(公告)号：US20210371397A1

公开(公告)日：2021-12-02

申请号：US17324867

申请日：2021-05-19

Applicant: AMGEN INC.

Inventor： Sebastien Caille ,  Kyle Quasdorf ,  Philipp C. Roosen ,  Xianqing Shi ,  Andrew Cosbie ,  Fang Wang ,  Zufan Wu ,  Archana Neergunda ,  Bin Peter Quan ,  Lianxiu Guan

IPC: C07D401/12 ,  C07D241/04

Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.

公开(公告)号：US11040956B2

公开(公告)日：2021-06-22

申请号：US16607940

申请日：2018-06-29

Applicant: AMGEN INC.

Inventor： Sebastien Caille ,  Kyle Quasdorf ,  Philipp Roosen ,  Xianqing Shi ,  Andrew Cosbie ,  Fang Wang ,  Zufan Wu ,  Archana Neergunda ,  Bin Peter Quan ,  Lianxiu Guan

IPC: C07D295/205 ,  C07D213/75 ,  C07D401/12 ,  C07D241/04

Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (I)